Clinical Trial Update: Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and efficacy of a three-dose MRKAd5 HIV-1 vaccine regimen in HIV-uninfected adults in South Africa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• MRKAd5 HIV-1 Gag/Pol/Nef (MRKAd5 HIV-1 Gag/Pol/Nef)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED